Revolution Medicines (RVMD) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Revolution Medicines
Is Revolution Medicines a buy right now? The alternative data leans yes. This RVMD stock analysis is built on the 25+ alternative data signals AltIndex tracks on Revolution Medicines every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 76/100: a Buy. The stock trades at $205.15 with a $44B market cap.
What’s driving the buy signal over the past 90 days: headcount (according to LinkedIn) up 34.9% to 1K employees, job postings up 27.6% to 277 open roles, and web traffic up 25.8% to 162K monthly visits. Stocks scoring above 60 have historically outperformed the S&P 500 over the following six months.
RVMD’s broader alt-data profile also covers business outlook (90% of employees positive), and sentiment (100/100). Every signal links to its own page with full history, the RVMD technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on RVMD is just below.
Revolution Medicines AI Stock Analysis
Revolution Medicines is a cutting-edge biotechnology company focused on the discovery and development of novel targeted therapies to treat cancer. The company leverages its deep understanding of cancer cell signaling and growth pathways to identify potential drug targets and create small molecule treatments.
Analysis generated August 8, 2026.
Recent Revolution Medicines Stock Alerts
|
Revolution Medicines | August 4 Price is up by 6.1% in the last 24h. |
|
Revolution Medicines | July 30 Price is up by 6.2% in the last 24h. |
|
Revolution Medicines | June 28 Insider Alert: Anders Jack is selling shares |
|
Revolution Medicines | June 25 Price is up by 6.4% in the last 24h. |
Revolution Medicines Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 162K | 25.8% | |
| Job Posts | 277 | 27.6% | |
| LinkedIn Employees | 1K | 34.9% | |
| Employee Recommend | 62 | 6.9% | |
| Business Outlook | 90 | 1.1% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 13 | 78.0% | |
| Stocktwits Mentions | 58 | 1.8% | |
| News Mentions | 1 | 0% | |
| Stocktwits Subscribers | 3K | 34.8% | |
| 4chan Mentions | 0 | N/A |
About Revolution Medicines (RVMD)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
| Price | $205.15 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $44B |
| Year Range | $35 – $205 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Revolution Medicines News
View more →
Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story?August 4 - Yahoo Entertainment |
|
 |
Can Revolution Medicines (RVMD) Justify Its Valuation On Daraxonrasib Survival Data?July 24 - Biztoc.com |
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review ProcessJuly 7 - Financial Post |
|
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?July 5 - Yahoo Entertainment |
|
 |
Revolution Medicines shares promising data around KRAS drug combinationJuly 3 - Biztoc.com |
Revolution Medicines Earnings & Financial Performance
View all earnings →Revolution Medicines Insider Trading Activity
View all →| Patel Sushil filed to sell 23,678 shares at $0.0. Jun 29 '26 |
| Patel Sushil filed to sell 23,778 shares at $0.0. Jun 29 '26 |
| Patel Sushil filed to sell 22,537 shares at $0.0. Jun 29 '26 |
| Patel Sushil filed to sell 23,078 shares at $0.0. Jun 29 '26 |
| Patel Sushil filed to sell 24,078 shares at $0.0. Jun 29 '26 |
Revolution Medicines Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Revolution Medicines
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
IQVIAIQV |
$238.70 2.7% | $39B | 59 |
 |
Royalty PharmaRPRX |
$56.77 0.9% | $33B | 56 |
 |
BiogenBIIB |
$207.94 0.8% | $31B | 45 |
 |
Alnylam PharmaceuticalsALNY |
$219.20 1.4% | $29B | 64 |
 |
IlluminaILMN |
$187.96 3.0% | $28B | 52 |
Explore Revolution Medicines Data
Frequently Asked Questions: Revolution Medicines (RVMD)
Revolution Medicines has an AltIndex AI Score of 76/100 (Buy). The score reflects positive alternative data signals. All investments carry risk.
76/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Revolution Medicines (RVMD) stock is $205.15 with a market cap of $44B.
As of today, Revolution Medicines’s PE (Price to Earnings) ratio is —.
View the latest Revolution Medicines insider transactions to see recent buying and selling activity by company executives and directors.
Check the Revolution Medicines congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The RVMD stock price chart above shows Revolution Medicines’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Revolution Medicines technical analysis for RSI, moving averages, and more.
See the stocks similar to Revolution Medicines section on this page for companies in the same industry ranked by market cap and AI Score.
